Dechra Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

De CEO Dechra Pharmaceuticals is Ian Page, benoemd in Nov2001, heeft een ambtstermijn van 22.17 jaar. De totale jaarlijkse vergoeding van { bedraagt £ 1.04M, bestaande uit 59.9% salaris en 40.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.36% van de aandelen van het bedrijf, ter waarde £ 15.64M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 4.3 jaar.

Belangrijke informatie

Ian Page

Algemeen directeur

UK£1.0m

Totale compensatie

Percentage CEO-salaris	59.9%
Dienstverband CEO	22.2yrs
Eigendom CEO	0.4%
Management gemiddelde ambtstermijn	4.8yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Sep 08

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Aug 18

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Aug 02

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Jun 10

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

May 08

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Apr 22

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

Feb 23

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Jan 29

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Jan 11

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Dec 04

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

Oct 15

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

Sep 25

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

Sep 11

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Sep 08

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?

Jun 17

Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?

Apr 09

Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet

Mar 05

Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 17

Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?

Feb 02

Analyse CEO-vergoeding

Hoe is Ian Page's beloning veranderd ten opzichte van Dechra Pharmaceuticals's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	UK£1m	UK£621k	-UK£28m
Mar 31 2023	n/a	n/a	UK£6m
Dec 31 2022	n/a	n/a	UK£40m
Sep 30 2022	n/a	n/a	UK£49m
Jun 30 2022	UK£2m	UK£597k	UK£58m
Mar 31 2022	n/a	n/a	UK£66m
Dec 31 2021	n/a	n/a	UK£73m
Sep 30 2021	n/a	n/a	UK£64m
Jun 30 2021	UK£3m	UK£551k	UK£56m
Mar 31 2021	n/a	n/a	UK£50m
Dec 31 2020	n/a	n/a	UK£44m
Sep 30 2020	n/a	n/a	UK£39m
Jun 30 2020	UK£2m	UK£517k	UK£34m
Mar 31 2020	n/a	n/a	UK£31m
Dec 31 2019	n/a	n/a	UK£29m
Sep 30 2019	n/a	n/a	UK£30m
Jun 30 2019	UK£3m	UK£500k	UK£31m
Mar 31 2019	n/a	n/a	UK£28m
Dec 31 2018	n/a	n/a	UK£25m
Sep 30 2018	n/a	n/a	UK£30m
Jun 30 2018	UK£3m	UK£500k	UK£36m
Mar 31 2018	n/a	n/a	UK£40m
Dec 31 2017	n/a	n/a	UK£43m
Sep 30 2017	n/a	n/a	UK£35m
Jun 30 2017	UK£3m	UK£490k	UK£26m

Compensatie versus markt: De totale vergoeding ($USD 1.31M ) Ian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 3.25M ).

Compensatie versus inkomsten: De vergoeding van Ian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ian Page (62 yo)

22.2yrs

Tenure

UK£1,037,000

Compensatie

Mr. Ian D. Page has been the Chief Executive Officer and Managing Director of Dechra Pharmaceuticals Plc since November 2001 and 1998 respectively and also serves as its Executive Director since June 13, 1...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Page	CEO, MD & Executive Director	22.2yrs	UK£1.04m	0.36% £ 15.6m
Paul Sandland	CFO & Executive Director	4.8yrs	UK£641.00k	0.010% £ 452.7k
Patrick Meeus	Chief Scientific Officer	1.5yrs	geen gegevens	geen gegevens
Jamie Adams	Chief Information Officer	1.6yrs	geen gegevens	geen gegevens
Katy Clough	Chief People Officer	no data	geen gegevens	geen gegevens
Mike Eldred	President of North America	no data	geen gegevens	geen gegevens
Melanie Hall	Company Secretary	6.5yrs	geen gegevens	geen gegevens

4.8yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van DPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ian Page	CEO, MD & Executive Director	26.6yrs	UK£1.04m	0.36% £ 15.6m
Paul Sandland	CFO & Executive Director	4.3yrs	UK£641.00k	0.010% £ 452.7k
Geeta Gopalan	Independent Non-Executive Director	less than a year	UK£36.00k	geen gegevens
Lawson MacArtney	Senior Independent Director	7.1yrs	UK£107.00k	0.0052% £ 227.2k
Alison Platt	Independent Non-Executive Chairman	3.8yrs	UK£207.00k	0.0033% £ 143.6k
Lisa Morrison	Designated Non-Executive Director	4.9yrs	UK£72.00k	0.0012% £ 53.3k
John Shipsey	Independent Non-Executive Director	1.6yrs	UK£73.00k	0.00053% £ 23.3k

4.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van DPH wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

Dechra Pharmaceuticals Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Less than half of directors are independent

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt

A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Consensus EPS estimates fall by 10%

We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt

Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125

Upcoming dividend of UK£0.13 per share at 1.6% yield

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Now 22% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289

Full year 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well

Dechra Pharmaceuticals PLC Announces Executive Changes

Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)

Less than half of directors are independent

Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?

Non-Executive Chairman recently bought UK£99k worth of stock

Consensus EPS estimates increase by 17%

Upcoming dividend of UK£0.12 per share

Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12

First half 2022 earnings: EPS misses analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package

CFO & Executive Director exercised options and sold UK£102k worth of stock

Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's

CEO, MD & Executive Director exercised options and sold UK£841k worth of stock

Board Member recently sold UK£875k worth of stock

Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29

With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Consensus EPS estimates increase to UK£0.52

Price target increased to UK£44.46

Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?